clonidine has been researched along with Ptosis, Eyelid in 21 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Apraclonidine (0." | 5.33 | The sensitivity and specificity of 0.5% apraclonidine in the diagnosis of oculosympathetic paresis. ( Acaroglu, G; Firat, E; Kansu, T; Kavuncu, S; Koc, F, 2005) |
| " Topical instillation of apraclonidine may represent a nonsurgical option for treatment of mild blepharoptosis in patients with light irides as it both elevates the upper eyelid margin and induces miosis, resulting in an increase in iris show and corresponding enhanced perception of upper eyelid elevation." | 3.88 | Effect of iris show on perceived upper eyelid height. ( Clark, TJE; Evans, JA; Shriver, EM; Wang, K, 2018) |
| "Apraclonidine is an alpha2-adrenergic agonist, which causes Muller muscles to contract quickly elevating the upper eyelid 1-3 mm." | 2.43 | The use of apraclonidine eyedrops to treat ptosis after the administration of botulinum toxin to the upper face. ( Scheinfeld, N, 2005) |
| "Apraclonidine hydrochloride is a topical ophthalmic solution with selective alpha-2 and weak alpha-1 receptor agonist activity that has the ability to elevate the eye lid." | 1.46 | Apraclonidine in the treatment of ptosis. ( Jankovic, J; Vijayakumar, D; Wijemanne, S, 2017) |
| "Apraclonidine (0." | 1.33 | The sensitivity and specificity of 0.5% apraclonidine in the diagnosis of oculosympathetic paresis. ( Acaroglu, G; Firat, E; Kansu, T; Kavuncu, S; Koc, F, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (23.81) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 9 (42.86) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Kraker, JA | 1 |
| Tajfirouz, DA | 1 |
| Bhatti, MT | 1 |
| Chen, JJ | 1 |
| Agha, M | 1 |
| Ismail, H | 1 |
| Sawaya, R | 1 |
| Salameh, J | 1 |
| Wijemanne, S | 1 |
| Vijayakumar, D | 1 |
| Jankovic, J | 1 |
| Osaki, TH | 1 |
| Osaki, MH | 1 |
| Evans, JA | 1 |
| Clark, TJE | 1 |
| Wang, K | 1 |
| Shriver, EM | 1 |
| Escrivá, E | 1 |
| Martínez-Costa, L | 1 |
| Steinsapir, KD | 1 |
| Groth, MJ | 1 |
| Boxrud, CA | 1 |
| McInnis, CP | 1 |
| Haynor, DR | 1 |
| Francis, CE | 1 |
| Brown, M | 1 |
| Malem, A | 1 |
| Shin, RK | 1 |
| Cheek, AG | 1 |
| Scheinfeld, N | 1 |
| Koc, F | 1 |
| Kavuncu, S | 1 |
| Kansu, T | 1 |
| Acaroglu, G | 1 |
| Firat, E | 1 |
| Chu, EA | 1 |
| Byrne, PJ | 1 |
| Saari, WS | 1 |
| Halczenko, W | 1 |
| Huff, JR | 1 |
| Guare, JP | 1 |
| Hunt, CA | 1 |
| Randall, WC | 1 |
| Lotti, VJ | 1 |
| Yarbrough, GG | 1 |
| Zetler, G | 1 |
| Malick, JB | 1 |
| Woolverton, WL | 1 |
| Wessinger, WD | 1 |
| Balster, RL | 1 |
| Harris, LS | 1 |
| Singer, M | 1 |
| Perrone, MH | 1 |
| Luttinger, D | 1 |
| Hamel, LT | 1 |
| Fritz, PM | 1 |
| Ferraino, R | 1 |
| Haubrich, DR | 1 |
| Maj, J | 1 |
| Michaluk, J | 1 |
| Rawłów, A | 1 |
| Rogóz, Z | 1 |
| Skuza, G | 1 |
1 review available for clonidine and Ptosis, Eyelid
| Article | Year |
|---|---|
The use of apraclonidine eyedrops to treat ptosis after the administration of botulinum toxin to the upper face.
Topics: Adrenergic alpha-Agonists; Blepharoptosis; Botulinum Toxins; Clonidine; Humans; Neuromuscular Agents | 2005 |
1 trial available for clonidine and Ptosis, Eyelid
| Article | Year |
|---|---|
Efficacy of apraclonidine eye drops in treating ptosis secondary to myasthenia gravis: A pilot clinical trial.
Topics: Blepharoptosis; Clonidine; Humans; Myasthenia Gravis; Ophthalmic Solutions; Retrospective Studies | 2023 |
19 other studies available for clonidine and Ptosis, Eyelid
| Article | Year |
|---|---|
Tachyphylaxis With Sustained Apraclonidine Use in the Treatment of Ptosis Associated With Horner Syndrome.
Topics: Blepharoptosis; Clonidine; Horner Syndrome; Humans; Tachyphylaxis | 2023 |
Apraclonidine in the treatment of ptosis.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Aged; Blepharoptosis; Botulinum Toxins; Clo | 2017 |
Re: Apraclonidine in the treatment of ptosis.
Topics: Blepharoptosis; Clonidine; Humans | 2017 |
Effect of iris show on perceived upper eyelid height.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Aged; Aged, 80 and over; Blepharoptosis; Cl | 2018 |
[Incomplete Horner's syndrome as a presenting sign of fourth ventricle ependymoma].
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Blepharoptosis; Cerebral Ventricle Neoplasms; Clonidine | 2013 |
Persistence of Upper Blepharoptosis After Cosmetic Botulinum Toxin Type A.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Blepharoptosis; Botulinum Toxins, Type A; Clonidine; Ey | 2015 |
Horner syndrome in fibromuscular dysplasia without carotid dissection.
Topics: Adrenergic alpha-2 Receptor Agonists; Blepharoptosis; Carotid Artery, Internal, Dissection; Clonidin | 2016 |
Preventing, identifying, and managing cosmetic procedure complications, part 1: soft-tissue augmentation and botulinum toxin injections.
Topics: Adrenergic alpha-2 Receptor Agonists; Blepharoptosis; Botulinum Toxins; Clonidine; Cosmetic Techniqu | 2016 |
Unequal pupils and ptosis.
Topics: Adrenergic alpha-2 Receptor Agonists; Aged; Anisocoria; Blepharoptosis; Carotid Arteries; Clonidine; | 2017 |
Teaching NeuroImages: Positive apraclonidine test in Horner syndrome.
Topics: Adrenergic alpha-Agonists; Adult; Blepharoptosis; Clonidine; Diskectomy; Female; Horner Syndrome; Hu | 2011 |
The sensitivity and specificity of 0.5% apraclonidine in the diagnosis of oculosympathetic paresis.
Topics: Adrenergic alpha-Agonists; Adult; Anisocoria; Blepharoptosis; Clonidine; Diabetic Neuropathies; Fema | 2005 |
Pharmacologic reversal of Horner's syndrome-related ptosis with apraclonidine.
Topics: Adrenergic alpha-Agonists; Adult; Blepharoptosis; Clonidine; Female; Horner Syndrome; Humans; Treatm | 2007 |
Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines.
Topics: Animals; Blepharoptosis; Cerebral Cortex; Clonidine; Male; Methoxamine; Mice; Pyridines; Rats; Recep | 1984 |
Clonidine and yohimbine separate the sedation and the ptosis caused by cholecystokinin octapeptide and ceruletide.
Topics: Animals; Apomorphine; Blepharoptosis; Catalepsy; Ceruletide; Clonidine; Drug Antagonism; Haloperidol | 1984 |
Clonidine: antidepressant potential?
Topics: Aggression; Animals; Arousal; Avoidance Learning; Blepharoptosis; Brain; Clonidine; Depressive Disor | 1981 |
Intravenous clonidine self-administration by rhesus monkeys.
Topics: Animals; Blepharoptosis; Clonidine; Cocaine; Dose-Response Relationship, Drug; Humans; Macaca mulatt | 1981 |
Botulinum toxin treatment of essential blepharospasm and hemifacial spasm.
Topics: Adrenergic alpha-Agonists; Blepharoptosis; Blepharospasm; Botulinum Toxins; Clonidine; Facial Muscle | 1996 |
In vivo assessment of napamezole, an alpha-2 adrenoceptor antagonist and monoamine re-uptake inhibitor.
Topics: Adrenergic alpha-Antagonists; Animals; Blepharoptosis; Brain; Clonidine; Conditioning, Operant; Desi | 1990 |
Central action of the antidepressant drug pirlindole.
Topics: 5-Hydroxytryptophan; Animals; Antidepressive Agents; Blepharoptosis; Body Temperature; Carbazoles; C | 1986 |